141 related articles for article (PubMed ID: 24583379)
1. Discovery of novel urea derivatives as dual-target hypoglycemic agents that activate glucokinase and PPARγ.
Li Y; Tian K; Qin A; Zhang L; Huo L; Lei L; Shen Z; Song H; Feng Z
Eur J Med Chem; 2014 Apr; 76():182-92. PubMed ID: 24583379
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and activity evaluation of GK/PPARγ dual-target-directed ligands as hypoglycemic agents.
Lu J; Lei L; Huan Y; Li Y; Zhang L; Shen Z; Hu W; Feng Z
ChemMedChem; 2014 May; 9(5):922-7. PubMed ID: 24737574
[TBL] [Abstract][Full Text] [Related]
3. Antidiabetic potential of a novel dual-target activator of glucokinase and peroxisome proliferator activated receptor-γ.
Lei L; Liu Q; Liu S; Huan Y; Sun S; Chen Z; Li L; Feng Z; Li Y; Shen Z
Metabolism; 2015 Oct; 64(10):1250-61. PubMed ID: 26189598
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel dual-action antidiabetic agents that inhibit glycogen phosphorylase and activate glucokinase.
Zhang L; Chen X; Liu J; Zhu Q; Leng Y; Luo X; Jiang H; Liu H
Eur J Med Chem; 2012 Dec; 58():624-39. PubMed ID: 23178962
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
Park K; Lee BM; Hyun KH; Lee DH; Choi HH; Kim H; Chong W; Kim KB; Nam SY
Bioorg Med Chem; 2014 Apr; 22(7):2280-93. PubMed ID: 24588963
[TBL] [Abstract][Full Text] [Related]
6. SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1.
Bertram LS; Black D; Briner PH; Chatfield R; Cooke A; Fyfe MC; Murray PJ; Naud F; Nawano M; Procter MJ; Rakipovski G; Rasamison CM; Reynet C; Schofield KL; Shah VK; Spindler F; Taylor A; Turton R; Williams GM; Wong-Kai-In P; Yasuda K
J Med Chem; 2008 Jul; 51(14):4340-5. PubMed ID: 18588279
[TBL] [Abstract][Full Text] [Related]
7. Benzamide derivatives as dual-action hypoglycemic agents that inhibit glycogen phosphorylase and activate glucokinase.
Zhang L; Li H; Zhu Q; Liu J; Chen L; Leng Y; Jiang H; Liu H
Bioorg Med Chem; 2009 Oct; 17(20):7301-12. PubMed ID: 19758809
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and SAR of novel glucokinase activators.
Cheruvallath ZS; Gwaltney SL; Sabat M; Tang M; Feng J; Wang H; Miura J; Guntupalli P; Jennings A; Hosfield D; Lee B; Wu Y
Bioorg Med Chem Lett; 2013 Apr; 23(7):2166-71. PubMed ID: 23434031
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus.
Park K; Lee BM; Kim YH; Han T; Yi W; Lee DH; Choi HH; Chong W; Lee CH
Bioorg Med Chem Lett; 2013 Jan; 23(2):537-42. PubMed ID: 23218712
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
[TBL] [Abstract][Full Text] [Related]
11. Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
Xu J; Lin S; Myers RW; Addona G; Berger JP; Campbell B; Chen HS; Chen Z; Eiermann GJ; Elowe NH; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; Malkani S; McMasters DR; Mitra K; Pachanski MJ; Tong X; Trujillo ME; Xu L; Zhang B; Zhang F; Zhang R; Parmee ER
Bioorg Med Chem Lett; 2017 May; 27(9):2069-2073. PubMed ID: 28284804
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents.
Itoh T; Murota I; Yoshikai K; Yamada S; Yamamoto K
Bioorg Med Chem; 2006 Jan; 14(1):98-108. PubMed ID: 16198578
[TBL] [Abstract][Full Text] [Related]
13. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators.
Iino T; Tsukahara D; Kamata K; Sasaki K; Ohyama S; Hosaka H; Hasegawa T; Chiba M; Nagata Y; Eiki J; Nishimura T
Bioorg Med Chem; 2009 Apr; 17(7):2733-43. PubMed ID: 19282189
[TBL] [Abstract][Full Text] [Related]
15. Small molecule glucokinase activators as novel anti-diabetic agents.
Leighton B; Atkinson A; Coghlan MP
Biochem Soc Trans; 2005 Apr; 33(Pt 2):371-4. PubMed ID: 15787609
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
Eiki J; Nagata Y; Futamura M; Sasaki-Yamamoto K; Iino T; Nishimura T; Chiba M; Ohyama S; Yoshida-Yoshimioto R; Fujii K; Hosaka H; Goto-Shimazaki H; Kadotani A; Ohe T; Lin S; Langdon RB; Berger JP
Mol Pharmacol; 2011 Dec; 80(6):1156-65. PubMed ID: 21937665
[TBL] [Abstract][Full Text] [Related]
17. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
Xu J; Lin S; Myers RW; Trujillo ME; Pachanski MJ; Malkani S; Chen HS; Chen Z; Campbell B; Eiermann GJ; Elowe N; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; McMasters DR; Mitra K; Tong X; Xu L; Zhang F; Zhang R; Addona GH; Berger JP; Zhang B; Parmee ER
Bioorg Med Chem Lett; 2017 May; 27(9):2063-2068. PubMed ID: 28284809
[TBL] [Abstract][Full Text] [Related]
18. Substituents at the naphthalene C3 position of (-)-Cercosporamide derivatives significantly affect the maximal efficacy as PPARγ partial agonists.
Furukawa A; Arita T; Fukuzaki T; Satoh S; Mori M; Honda T; Matsui Y; Wakabayashi K; Hayashi S; Araki K; Ohsumi J
Bioorg Med Chem Lett; 2012 Feb; 22(3):1348-51. PubMed ID: 22225641
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators.
Mao W; Ning M; Liu Z; Zhu Q; Leng Y; Zhang A
Bioorg Med Chem; 2012 May; 20(9):2982-91. PubMed ID: 22459213
[TBL] [Abstract][Full Text] [Related]
20. Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
Henry JR; Li Y; Warshawsky AM; Brozinick JT; Hawkins ED; Misener EA; Briere DA; Montrose-Rafizadeh C; Zink RW; Yumibe NP; Ajamie RT; Wilken B; Devanarayan V
Bioorg Med Chem Lett; 2006 Dec; 16(24):6293-7. PubMed ID: 17005393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
